Overview

Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

Status:
Active, not recruiting

Trial end date:
2024-11-30

Target enrollment:

Participant gender:

Summary

This research study is studying two drugs at different time points as a possible treatment for advanced renal cell cancer The drugs involved in this study are: Nivolumab Ipilimumab

Phase:

Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute
Toni Choueiri, MD

Collaborator:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Ipilimumab
Nivolumab